Literature DB >> 3285791

Tumors of the immunocompromised patient.

I Penn1.   

Abstract

Immunocompromised patients are prone to develop certain malignancies, particularly involving cells of the immune system itself (1-3). In this chapter we describe the various neoplasms, note the differences between these and similar cancers in the general population, emphasize similar tumor patterns in different types of immunodeficiency, and discuss possible etiologic factors.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3285791     DOI： 10.1146/annurev.me.39.020188.000431

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN： 0066-4219            Impact factor:   13.739


  39 in total

1.  Rapid proliferation of a different clone early after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.

Authors:  Takehiko Mori; Junichi Tamaru; Michihide Tokuhira; Shigehisa Mori; Hiroshi Suzuki; Toru Abe; Tsutomu Takeuchi
Journal:  Int J Hematol       Date:  2002-10       Impact factor: 2.490

2.  Acute myelogenous leukemia in a rheumatoid arthritis patient under cyclosporine A therapy.

Authors:  P Casoli; B Tumiati
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

Review 3.  The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.

Authors:  I M Svane; M Boesen; A M Engel
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

Review 4.  Regulatory considerations for clinical development of cancer vaccines.

Authors:  Bridget Theresa Heelan
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?

Authors:  John Stagg; Fabrice Andre; Sherene Loi
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

6.  Kaposi's sarcoma of the colon in a young HIV-negative woman with Crohn's disease.

Authors:  T Puy-Montbrun; F Pigot; P N Vuong; R Ganansia; J Denis
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

Review 7.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 8.  Harnessing the immune system to treat cancer.

Authors:  Nina Bhardwaj
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy.

Authors:  Rachel L Mintz; Madeleine A Gao; Kahmun Lo; Yeh-Hsing Lao; Mingqiang Li; Kam W Leong
Journal:  Adv Biosyst       Date:  2018-08-17

10.  p53 expression in circulating lymphocytes of non-melanoma skin cancer patients from an arsenic contaminated region in Mexico. A pilot study.

Authors:  Ana M Salazar; Emma Calderón-Aranda; Mariano E Cebrián; Monserrat Sordo; Andrés Bendesky; Arístides Gómez-Muñoz; Leonor Acosta-Saavedra; Patricia Ostrosky-Wegman
Journal:  Mol Cell Biochem       Date:  2004-01       Impact factor: 3.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.